<DOC>
	<DOCNO>NCT02064816</DOCNO>
	<brief_summary>This open-label , multi-center , 12-week , randomize , control , parallel group , Phase 4 study ass whether morning administration interferon beta 1a ( Rebif® ) lead low severity flu-like symptom ( FLS ) compare even administration , subject relapse multiple sclerosis ( RMS ) .</brief_summary>
	<brief_title>A Study Rebif® Subjects With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Males females 18 60 year age Female subject must neither pregnant breastfeeding must lack childbearing potential . Furthermore , female subject must pregnant least three month prior enter study Subjects RMS accord revise McDonald Criteria ( 2010 ) Subjects expand disability status scale ( EDSS ) score less 6.0 Subjects naive treatment eligible treatment Rebif® 44 three time week , patient receive glatiramer acetate washout least one month , patient receive treatment natalizumab fingolimod washout least three month Subjects able selfinject treatment use RebiSmart® Subjects willing able comply protocol duration study Subjects give write informed consent take part study Subjects disease MS could better explain his/her sign symptom Subjects receive immunosuppressive agent within 3 month prior Baseline Subjects receive corticosteroid within 30 day prior Baseline Subjects MS relapse within 30 day prior Baseline Subjects inadequate liver function bone marrow reserve define protocol Subjects moderate severe renal impairment Subjects visual physical impairment precludes subject selfinjecting treatment use RebiSmart® Subjects hypersensitivity natural recombinant interferon , excipients Subjects contraindication treatment interferon ( IFN ) beta 1a accord Summary Product Characteristics ( SmPC ) Subjects contraindication treatment ibuprofen/paracetamol accord SmPC Obese subject , define body mass index great 30 kilogram per square meter ( kg/m^2 ) Subjects participated investigational trial within 30 day Baseline Subjects significant disease Investigator 's opinion would exclude subject trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Rebif®</keyword>
</DOC>